Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMTYOPD)

• Drug Name: Dinoprostone Drug Info
• Synonyms: Cervidil; Dinoproston; Dinoprostona; Dinoprostonum; Prepidil; Propess; Prostenon; Prostin; Prepidil Gel; Prostarmon E;Prostin E; Dinoprostone Prostaglandin E2; Minprositin E2; Minprostin E2; PGE2; PGE2 alpha; PGE2alpha; Prostaglandin E2; Prostaglandin E2 alpha; Prostaglandin E2alpha; Prostarmon E2; Prostin E2; U 12062; [3H]PGE2; Alpha, PGE2; Alpha, Prostaglandin E2; BML1-F07; Cervidil (TN); Dinoprostona [INN-Spanish]; Dinoprostone beta-Cyclodextrin Clathrate; Dinoprostonum [INN-Latin]; E2 alpha, Prostaglandin; E2, Prostaglandin; E2alpha, Prostaglandin; Gel, Prepidil; L-PGE2; L-Prostaglandin E2; Prepidil (TN); Propess (TN); Prostin E2 (TN); U-12062; BMS-279654 & PGE2; Dinoprostone (JAN/USP/INN); Dinoprostone [USAN:INN:BAN:JAN]; L-7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid; (15S)-Prostaglandin E2; (5Z,11-alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11.alpha.,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dien-1-oic; (5Z,11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprosta-5,13-dienoic acid; (5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (5Z,13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; (5Z,13E)-(15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dienoate; (5Z,13E,15S)-11alpha,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid; (E,Z)-(1R,2R,3R)-7-(3-Hydroxy-2-((3S)-(3-hydroxy-1-octenyl))-5-oxocyclopentyl)-5-heptenoic acid; (Z)-7-[(1R,2R,3R)-3-Hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]hept-5-enoic acid; 5-Heptenoic acid, 7-(3-hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-(8CI); 7-(3-Hydroxy-2-(3-hydroxy-1-octenyl)-5-oxocyclopentyl)-5-heptenoic acid
• Therapeutic Class: Prostaglandins
• Cross-matching ID:
  PubChem CID: 5280360
  ChEBI ID: CHEMBL548
  CAS Number: CAS 363-24-6
  TTD Drug ID: D06FEA
  VARIDT Drug ID: DR00102
  INTEDE Drug ID: DR0511
  ACDINA Drug ID: D01006

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Protein export	1.89	8.18e-3	17/23 (73.91%)	SRPRA;SRP54;SEC61B;...
Viral protein interaction with cytokine and cytokine re...	1.86	8.18e-3	84/100 (84%)	CXCL13;IL6;CCL2;...
Ribosome biogenesis in eukaryotes	1.78	3.54e-2	52/108 (48.15%)	GTPBP4;GNL3;REXO2;...
Tight junction	-1.69	3.99e-2	130/169 (76.92%)	MYH9;MAP3K1;TUBA1A;...
MAPK signaling pathway	-1.69	4.20e-2	272/294 (92.52%)	FLNC;RASGRP3;TGFBR2;...
Oxytocin signaling pathway	-1.69	4.55e-2	128/154 (83.12%)	PPP1R12A;GNAO1;ADCY8;...
Pancreatic cancer	-1.72	3.72e-2	75/76 (98.68%)	TGFBR2;CDKN1A;TP53;...
Colorectal cancer	-1.75	2.85e-2	84/86 (97.67%)	TGFBR2;CDKN1A;TP53;...
Regulation of actin cytoskeleton	-1.75	3.03e-2	185/218 (84.86%)	SOS2;NCKAP1L;ACTR3;...
Non-small cell lung cancer	-1.77	2.33e-2	70/72 (97.22%)	CDKN1A;TP53;RXRA;...
SNARE interactions in vesicular transport	-1.82	1.06e-2	19/33 (57.58%)	STX8;STX7;STX18;...
Melanoma	-1.88	2.07e-3	68/72 (94.44%)	CDKN1A;TP53;BAX;...
Retinol metabolism	-1.89	2.48e-3	41/68 (60.29%)	PNPLA4;BCO1;CYP2B6;...
Steroid biosynthesis	-1.92	3.10e-3	19/20 (95%)	DHCR24;CYP51A1;EBP;...
p53 signaling pathway	-1.93	4.14e-3	63/73 (86.3%)	CDKN1A;TP53;BAX;...
Thyroid cancer	-1.99	6.21e-3	36/37 (97.3%)	CDKN1A;TP53;CTNNB1;...
Bacterial invasion of epithelial cells	-2.16	0.00e+0	59/77 (76.62%)	CLTA;ACTR3;ELMO2;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H	Show ▼

Fibroblast

Nasopharyngeal carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
FIBRNPC	CVCL_UK07	Homo sapiens	10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H, 24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	10uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H	Show ▼